NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. Addi ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties an ...

Following our recent update on Royalty Pharma plc (NASDAQ: RPRX ) - Key Strategic Updates To Be Priced In , we are back to comment on the company's quarterly results. Since our strong buy recommendation released in earlyBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ 110 East 59 Street th New York, New York 10022 (Address of principal executive offices and Zip Code) (212) 883-0200 (Registrant's telephone ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). "We are excited to collaborate with Biogen on litifilimab," said Pablo Legorreta, Royalty Pharma's fou ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both sys ...

Strong Royalty Receipts growth; Portfolio Receipts growth impacted by a high base of comparison Capital Deployment of $2.8 billion in 2024 with royalties on eight new therapies added to the portfolio Exciting new product launches expected across the royalty portfolio in 2025 • Royalty Pharma to benefit in 2025 from new product launches, including Servier's Voranigo, Bristol Myers Squibb's Cobenfy, Ascendis' Yorvipath, Syndax and Incyte's Niktimvo and Geron's Rytelo. Financial guidance for full year 2025 (ex ...

Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Conference Call February 11, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP, Head-Research and Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call Participants Geoffrey Meacham - Citi Christopher Schott - JPMorgan Chase & Co Michael Nedelcovych - TD Cowen Chris Shibutani - Goldman Sachs Dina R ...

Core Insights - Royalty Pharma reported $742 million in revenue for Q4 2024, a year-over-year increase of 0.8%, with an EPS of $1.15, matching the previous year's figure [1] - The revenue exceeded the Zacks Consensus Estimate of $725.33 million by 2.30%, and the EPS surpassed the consensus estimate of $1.09 by 5.50% [1] Financial Performance Metrics - The company’s shares returned +5.8% over the past month, outperforming the Zacks S&P 500 composite's +4.2% change, and currently holds a Zacks Rank 3 (Hold) [3] - Total Portfolio Receipts from Royalty Receipts Products amounted to $729 million, exceeding the average estimate of $711.32 million, reflecting a year-over-year increase of +61.5% [4] Product-Specific Performance - Cystic fibrosis franchise generated $237 million, surpassing the average estimate of $219.16 million, with a year-over-year change of +114.4% [4] - Tysabri reported $61 million, slightly above the estimated $60.23 million, marking a +171.1% increase year-over-year [4] - Imbruvica generated $46 million, exceeding the estimate of $45.80 million, with a +180.6% year-over-year change [4] - Xtandi also reported $46 million, surpassing the average estimate of $44.22 million, reflecting a +205.6% increase year-over-year [4] - Promacta generated $44 million, exceeding the estimate of $39.82 million, with a +134.6% year-over-year change [4] - Evrysdi reported $56 million, above the estimate of $53.49 million, marking a +183.5% increase year-over-year [4] - Trodelvy generated $11 million, slightly below the estimate of $11.66 million, with a +119.5% year-over-year change [4] - Trelegy reported $74 million, exceeding the average estimate of $72.55 million, reflecting a +23% year-over-year change [4]

Core Insights - Royalty Pharma plc reported strong financial results for Q4 and full year 2024, with double-digit growth in Royalty Receipts and a significant capital deployment of $2.8 billion on royalties [2][7][21] - The company anticipates continued growth in 2025, with Portfolio Receipts expected to be between $2,900 million and $3,050 million, reflecting a growth rate of 4% to 9% [5][29] - Royalty Pharma has initiated a $3 billion share repurchase program and acquired its external manager, which is expected to enhance shareholder value and reduce costs [2][15][22] Financial Performance - Q4 2024 Portfolio Receipts were $742 million, a 1% increase from Q4 2023, while full year 2024 Portfolio Receipts decreased by 8% to $2,801 million [6][12][58] - Royalty Receipts grew by 12% in Q4 2024 to $729 million and by 13% for the full year to $2,771 million, driven by strong performances from key products [8][11][59] - Adjusted EBITDA for Q4 2024 was $669 million, a 2% decrease from the previous year, while full year Adjusted EBITDA was $2,565 million, down 9% [19][49] Capital Deployment and Investments - The company deployed $2.8 billion in capital during 2024, acquiring royalties on eight new therapies, and expects to benefit from new product launches in 2025 [4][17][21] - Royalty Pharma's liquidity position as of December 31, 2024, included cash and cash equivalents of $929 million and total debt of $7.8 billion [13][51] - The company repurchased approximately 8 million Class A ordinary shares for $230 million in 2024, with plans for further repurchases in 2025 [14][15] Strategic Initiatives - The acquisition of RP Management, LLC is expected to generate significant cost savings and enhance shareholder alignment, with projected savings exceeding $1.6 billion over ten years [22][23] - Royalty Pharma's transaction pipeline remains robust, with a focus on value-enhancing royalty acquisitions [2][4] - The company has a disciplined capital allocation strategy, bolstered by recent cash proceeds from the sale of MorphoSys Development Funding Bonds [20]